bpc-157 human clinical trials back pain or musculoskeletal Data: Promising, But Not Proven In Humans, Early animal studies suggest BPC-157 may reduce behaviors in inflammatory and non-inflammatory models, including reduced allodynia. But this Frontiers | Stable Gastric Pentadecapeptide

In rats with short bowel syndrome, BPC-157 caused immediate weight gain and improved intestinal features following oral and intraperitoneal administration [17]

A study indicated that untreated patients with adrenal insufficiency demonstrated increased sleep fragmentation, increased REM latency, and decreased amount of time in REM sleep, findings that may explain the patients' fatigue (54)

BPC 157 upregulates VEGFR2 expression in rats with hind limb ischemia and endothelial cell culture

HUBERMAN: And of course, there is no reason why anyone should use these compounds unless they absolutely feel they need to and there's a potential benefit there